NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of...
Related Questions
How will Elanco Animal Health's inclusion in the S&P MidCap 400 affect its shortāterm price dynamics and trading volume?
What impact will the index rebalancing have on institutional and ETF allocations to ELAN and Sarepta Therapeutics, and how might this drive price movements?
Are there broader sector implications or spillāover effects for other animalāhealth and biotech stocks resulting from this swap, and what does this mean for tradeālevel strategies?